Plant Psychedelics
Ibogaine
The most medically promising and the most physically dangerous psychedelic substance on this site. Ibogaine can interrupt opioid addiction in a single session — and it can also stop your heart. This is not a substance for unsupervised use. Period.
The Basics
This substance can kill you
Ibogaine is derived from the root bark of the West African shrub Tabernanthe iboga, used for centuries in Bwiti spiritual practice in Gabon and Cameroon. Its modern medical interest centers on a remarkable property: a single flood dose can dramatically reduce or eliminate opioid withdrawal symptoms and cravings, sometimes for months.
The experience itself is long (12–36 hours), intense, and often described as visionary rather than recreational — a panoramic life review, encounters with archetypal imagery, and deep psychological confrontation. It is nothing like psilocybin or LSD. Most people describe it as difficult, exhausting, and profoundly meaningful.
⚠ Cardiac toxicity — this is the critical risk
Ibogaine prolongs the QT interval — the electrical recovery phase of your heartbeat. This can trigger fatal cardiac arrhythmias (Torsades de Pointes). Deaths have occurred at ibogaine treatment centers, including in patients with no known pre-existing heart conditions. A recent EKG (within 2 weeks), liver function panel, and electrolyte panel are absolute minimums before any ibogaine session. This substance requires medical supervision. Home use at flood doses is reckless.
The Science
Multi-target pharmacology
Ibogaine hits more receptor systems than almost any other psychoactive substance. This broad pharmacology is why it works on addiction — and why it's dangerous.
Opioid receptors
Ibogaine and its metabolite noribogaine bind to mu, kappa, and delta opioid receptors. Noribogaine persists in the body for weeks and may be responsible for sustained anti-craving effects long after the acute experience ends.
NMDA antagonism
Like ketamine, ibogaine blocks NMDA receptors. This may contribute to its anti-addictive properties and its dissociative visual effects. NMDA antagonism is a shared feature of several substances showing anti-addiction promise.
Serotonin transport
Ibogaine inhibits serotonin reuptake. This contributes to the mood effects and carries implications for drug interactions — combining with SSRIs or other serotonergic substances increases serotonin syndrome risk.
hERG channel blockade
This is the mechanism behind cardiac risk. Ibogaine blocks hERG potassium channels, prolonging the QT interval. This is the same mechanism that has pulled pharmaceutical drugs from the market. It's a serious, dose-dependent risk.
Harm Reduction
If this is something you're considering
Ibogaine is not a substance for experimentation. It's a medical intervention that requires medical oversight. The information below is for people who are seriously considering ibogaine treatment for addiction, which is its primary modern use case.
Medical screening is non-negotiable. EKG within 2 weeks, liver function panel, complete metabolic panel, electrolyte levels. Any QT prolongation, liver impairment, or electrolyte imbalance is a contraindication. Facilities that skip screening are dangerous.
Cardiac monitoring during the session. Continuous EKG monitoring throughout the experience is the medical standard of care. Facilities without cardiac monitoring capability should be avoided.
Drug clearance before treatment. Opioids, stimulants, benzodiazepines, SSRIs, and many other substances must be cleared before ibogaine administration. Methadone requires an especially long clearance period (weeks, not days). Fentanyl's unpredictable tissue storage makes clearance timing difficult.
The experience is long and physically demanding. 12–36 hours of active effects, followed by days of recovery. Nausea, ataxia (loss of coordination), and sensitivity to light and sound are common. You will need support afterward.
Ibogaine interrupts addiction — it doesn't cure it. The window of reduced cravings it creates must be used for building new patterns, accessing therapy, and restructuring your life. Without follow-up support, relapse rates climb back up.
Clinic vetting matters enormously. Research the facility's medical staff, screening protocols, cardiac monitoring capability, emergency response plan, and aftercare program. Patient deaths have occurred at facilities with inadequate medical oversight.
Legal Landscape
Illegal in the U.S., treatment available abroad
Treatment Available
Mexico · Costa Rica · Brazil · New Zealand · Canada (Special Access Programme) · Several Caribbean nations · South Africa
Unregulated
Many countries have no specific ibogaine legislation · Gray market clinics operate in some jurisdictions · Quality and safety vary enormously
Illegal
United States (Schedule I) · France · Belgium · Denmark · Sweden · Switzerland · Poland
Tim's Take
Ibogaine is one of the most specifically useful and one of the most specifically dangerous substances on this site.
The useful part: ibogaine has a legitimate, decades-old track record in interrupting opioid addiction. A single dose reportedly resets tolerance, dramatically reduces withdrawal symptoms, and produces a long reflective experience that a lot of people describe as being confronted with the story of their own life. Harvard and other research groups have been looking at it seriously. The therapeutic potential is real and it's different in kind from what other psychedelics offer.
The dangerous part: ibogaine prolongs the QT interval on your heart's electrical cycle. This is the mechanism behind torsades de pointes, a life-threatening arrhythmia. People have died on ibogaine, including at therapeutic doses in clinical settings, specifically from cardiac events. This is not a hypothetical risk. It's the reason ibogaine clinics that do it right require medical screening including EKG and electrolyte panels before dosing, cardiac monitoring during the session, and pre-treatment correction of any potassium or magnesium abnormalities.
Ibogaine is also exhausting in a way most substances aren't. The experience is 24 to 36 hours long, physically and emotionally grueling, and not something anyone describes as recreational. People who do it for addiction interruption talk about it as one of the hardest things they've ever done. People who do it for curiosity usually don't repeat.
If ibogaine is something you're considering for opioid dependence, the path is a properly screened, medically supervised clinic, not a retreat center or a do-it-yourself attempt. The cardiac risk is what separates ibogaine from every other psychedelic on this site, and that risk is not something that can be mitigated by being careful at home. Iboga, the plant source, has also been the subject of conservation and sovereignty concerns because of Gabon's traditional Bwiti use, which is worth knowing about if this path is calling you.
If you or someone you know needs support
For substance use support, SAMHSA's helpline is available 24/7 at 1-800-662-4357 — free, confidential, and available in English and Spanish. The Fireside Project provides psychedelic-specific emotional support.
Fireside: Call or text · Available 24/7 · Free · Non-judgmental
Know Before You Go
Based on documented risks and harm reduction literature, practitioners typically advise the following.
Cardiac risk is real and fatal outcomes are documented. EKG screening and cardiac monitoring are non-negotiable.
This is not a home-use substance. Medical supervision is the minimum standard of care.
12–36 hours of active effects. Days of recovery. This is the most physically demanding psychedelic experience.
Ibogaine interrupts addiction — it doesn't cure it. Without follow-up support, the window closes.
Drug clearance is critical. Methadone requires weeks. Fentanyl clearance timing is unpredictable.
SAMHSA: 1-800-662-4357 · 24/7 · Free · Confidential
Last reviewed